The prime minister’s directive banning the production and use of substandard syringes is a necessary response to a matter that directly concerns public health. Medical devices that fail to meet prescribed standards expose patients to avoidable risks, undermine confidence in healthcare institutions and reflect serious regulatory lapses. The order is therefore justified. The real challenge, however, lies in ensuring that it is implemented consistently rather than remaining a one-off administrative intervention. The circulation of defective syringes points to weaknesses that extend beyond individual manufacturers. It raises questions about the effectiveness of quality control, market surveillance and enforcement mechanisms that are meant to prevent unsafe medical products from reaching hospitals, clinics and pharmacies. Regulatory oversight cannot be limited to reacting after defective products have entered the supply chain. It must be proactive, backed by regular inspections, independent testing and swift enforcement against violations. Accountability must also extend to manufacturers and distributors who compromise patient safety for commercial gain. Firms found producing or marketing substandard medical devices should face stringent penalties, including the cancellation of licenses and criminal prosecution where the law permits. At the same time, regulatory agencies must be adequately resourced and insulated from political or........

© The Patriot